KR20110091778A - 사상 박테리오파지를 이용하는 파킨슨병의 치료방법 - Google Patents

사상 박테리오파지를 이용하는 파킨슨병의 치료방법 Download PDF

Info

Publication number
KR20110091778A
KR20110091778A KR1020117014511A KR20117014511A KR20110091778A KR 20110091778 A KR20110091778 A KR 20110091778A KR 1020117014511 A KR1020117014511 A KR 1020117014511A KR 20117014511 A KR20117014511 A KR 20117014511A KR 20110091778 A KR20110091778 A KR 20110091778A
Authority
KR
South Korea
Prior art keywords
bacteriophage
filamentous
antibody
synuclein
parkinson
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117014511A
Other languages
English (en)
Korean (ko)
Inventor
베카 솔로몬
하임 엠. 디맨트
Original Assignee
라모트 앳 텔-아비브 유니버시티 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라모트 앳 텔-아비브 유니버시티 리미티드 filed Critical 라모트 앳 텔-아비브 유니버시티 리미티드
Publication of KR20110091778A publication Critical patent/KR20110091778A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020117014511A 2008-11-24 2009-11-24 사상 박테리오파지를 이용하는 파킨슨병의 치료방법 Withdrawn KR20110091778A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24
US61/117,446 2008-11-24

Publications (1)

Publication Number Publication Date
KR20110091778A true KR20110091778A (ko) 2011-08-12

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117014511A Withdrawn KR20110091778A (ko) 2008-11-24 2009-11-24 사상 박테리오파지를 이용하는 파킨슨병의 치료방법

Country Status (16)

Country Link
US (1) US20110286970A1 (cg-RX-API-DMAC7.html)
EP (2) EP2478911A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012509672A (cg-RX-API-DMAC7.html)
KR (1) KR20110091778A (cg-RX-API-DMAC7.html)
CN (1) CN102223887B (cg-RX-API-DMAC7.html)
AU (1) AU2009316326A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921557A2 (cg-RX-API-DMAC7.html)
CA (1) CA2744339A1 (cg-RX-API-DMAC7.html)
CO (1) CO6390112A2 (cg-RX-API-DMAC7.html)
IL (1) IL213120A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011005430A (cg-RX-API-DMAC7.html)
NZ (1) NZ592928A (cg-RX-API-DMAC7.html)
RU (1) RU2011125971A (cg-RX-API-DMAC7.html)
SG (1) SG171791A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010060073A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104701B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ, インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージg3pアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
WO2002042321A2 (en) * 2000-11-24 2002-05-30 Isis Innovation Limited Mixed fibrils
IL163812A0 (en) * 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
JP5096169B2 (ja) * 2005-02-01 2012-12-12 ラモット・アット・テルアビブ・ユニバーシティ アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
MX2008010612A (es) * 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
US20090324554A1 (en) * 2006-07-21 2009-12-31 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
AU2009316326A1 (en) 2010-05-27
MX2011005430A (es) 2011-10-28
CO6390112A2 (es) 2012-02-29
ZA201104701B (en) 2012-09-26
HK1162964A1 (en) 2012-09-07
SG171791A1 (en) 2011-07-28
EP2478911A1 (en) 2012-07-25
JP2012509672A (ja) 2012-04-26
US20110286970A1 (en) 2011-11-24
NZ592928A (en) 2012-12-21
IL213120A0 (en) 2011-07-31
CN102223887A (zh) 2011-10-19
EP2358377A2 (en) 2011-08-24
WO2010060073A2 (en) 2010-05-27
WO2010060073A3 (en) 2010-09-02
CA2744339A1 (en) 2010-05-27
BRPI0921557A2 (pt) 2019-09-24
CN102223887B (zh) 2013-11-06
RU2011125971A (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
CN102223887B (zh) 使用丝状噬菌体治疗帕金森病的方法
EP2054515B1 (en) Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
US20220403021A1 (en) Targeting Synaptogyrin-3 in Tauopathy Treatment
Spencer et al. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders
JP2009529320A (ja) 脳への送達のための抗体および免疫複合体のバインダーとしてのプロテインaをディスプレイする繊維状バクテリオファージ
US20110182948A1 (en) Method for treating disease characterized by plaque
US8980547B2 (en) Method for treating neurodegenerative tauopathy
Teng et al. Efficient amyloid-β degradation in Alzheimer’s disease using SPYTACs
EP2758077B1 (en) Compounds for use in the treatment of alzheimer's disease
HK1162964B (en) Method for treating parkinson' s disease using filamentous bacteriophage
US20240248100A1 (en) Septapeptides associated with neurodegeneracy
Bonfante Discovery and characterisation of anti-amyloid beta fibril antibodies from naive phage display VHH libraries
JP2023547785A (ja) プリオン-Fc領域融合タンパク質及びそれらの使用
Ross The Development of Antibody Loaded Liposomes for the Treatment of Alzheimer's Disease
Solomon In Vivo Targeting of Amyloid Plaques Via Intranasal Administration of Phage Anti-β-Amyloid Antibodies
Peres Role for lipids in the cellular transmission of α-synuclein
Jin Development of a small alpha-synuclein-knockdown peptide as a potential therapy for Parkinson’s disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110623

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid